MannKind announced new clinical and real-world data for Afrezza (inhaled insulin) presented at the ADA 2026 Scientific Sessions, following the FDA approval for pediatric use (ages 6+) in May 2026. Key findings include greater treatment satisfaction in pediatric patients, comparable efficacy to rapid-acting analogs, potential use with automated insulin delivery systems, and earlier pharmacodynamic effect completion. The company also reported positive real-world evidence on lung cancer risk and FUROSCIX benefits in heart failure patients.

MannKind Corporation announced FDA approval of Afrezza®, the first and only inhaled mealtime insulin for children and adolescents aged 6 and older with diabetes. The company will host a conference call on May 29, 2026 at 4:30 p.m. Eastern with CEO Michael Castagna and other executives to discuss the approval.

MannKind Corporation reported Q1 2026 total revenues of $90.2M, representing 15% growth compared to Q1 2025. The company announced CEO Michael Castagna will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3. MannKind also plans to showcase new data on inhaled insulin (Afrezza®) in pediatric care, pregnancy, and use with automated insulin delivery systems at ADA 2026.

The point-of-care diagnostics market has reached $58.76 billion globally in 2026, growing at nearly 10% annually, with projections to reach $114.65 billion by 2035. Five companies are leading this structural shift toward decentralized, consumer-facing healthcare: VentriPoint Diagnostics is expanding globally with AI-powered cardiac imaging; Hims & Hers partnered with Novo Nordisk to offer affordable GLP-1 medications including Wegovy; MannKind is presenting clinical data on Afrezza inhaled insulin; and Ginkgo Bioworks launched Cloud Lab for remote access to autonomous lab infrastructure.

Avaí Bio announced it has initiated manufacturing of a Master Cell Bank of genetically modified cells that overexpress the α-Klotho protein, a key anti-aging protein that naturally declines by 50% after age 40. The milestone represents a transition from research to production infrastructure for their Klothonova anti-aging platform using Cell-in-a-Box® encapsulation technology. The cell therapy sector is rapidly expanding, with the global market projected to grow from $10.4 billion to over $45 billion by 2035.

MannKind stock fell over 7% after reporting Q4 2025 earnings that showed a 46% revenue increase to $112 million, beating analyst estimates. However, the company's net income declined significantly to $1.5 million ($0.01 per share), missing the consensus estimate of $0.02 per share. The decline was driven by increased costs from integrating the Furoscix acquisition and higher R&D expenses. Despite the miss on profitability, the analyst argues the sell-off was unjustified given the company's strong pipeline.

MannKind Corporation announced that CEO Michael Castagna will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The company will also report its fourth quarter and full year 2025 financial results on the same date. Additionally, MannKind announced the first patient enrollment in the INHALE-1ST pediatric study evaluating Afrezza for youth with newly-diagnosed Type 1 Diabetes.

The healthcare sector is experiencing a structural shift toward regenerative medicine and longevity infrastructure, valued at $27 trillion by 2030. Several biotech companies are advancing cell therapy and gene-targeted treatments: Avant Technologies presented cell encapsulation technology for diabetes at a European symposium, MannKind received FDA label updates for Afrezza inhaled insulin, Altimmune gained FDA Breakthrough Therapy Designation for pemvidutide in liver disease, Lineage Cell Therapeutics received a gene-edited cell line from Factor Bioscience, and Arrowhead Pharmaceuticals initiated a Phase 1/2a trial for a dual-gene silencing RNAi therapeutic for cardiovascular disease.

The biotech sector is experiencing significant growth driven by FDA regulatory shifts favoring advanced cell and gene therapies. Companies like Avant Technologies, MannKind, Vertex Pharmaceuticals, Fate Therapeutics, and Ardelyx are positioned to benefit from a projected $88.85 billion next-gen treatment market by 2030 and $9.06 trillion biotech sector by 2035. Key catalysts include FDA approvals, clinical trial progress, and record revenue achievements across multiple therapeutic areas including diabetes, kidney disease, and rare genetic disorders.

MannKind Corporation announced strong 2026 growth catalysts including FDA decisions on Afrezza label updates and pediatric indications, FUROSCIX ReadyFlow Autoinjector approval, and pipeline progress with Nintedanib DPI and Bumetanib DPI. The company closed 2025 with record Q4 revenue exceeding $100 million and completed the acquisition of scPharmaceuticals.

MannKind CEO Michael Castagna sold 65,804 shares on December 17, 2025, for approximately $395,482. The sale represents a routine transaction aligned with his typical trading cadence and is not considered a warning sign. The company is performing well with strong Q3 results, FDA acceptance of a pediatric Afrezza application, and completion of the scPharmaceuticals acquisition. However, with a P/E ratio around 60, current investors may consider selling, while prospective buyers should wait for a price drop.

Nitorum Capital fully exited its stake in Lantheus Holdings, selling 344,444 shares worth $28.2 million in Q3. The exit comes as Lantheus faces significant headwinds including a 77% year-over-year earnings decline, declining sales of its flagship prostate cancer imaging agent, CEO retirement, and margin compression despite strong revenue generation.